SynthesisJournal of translational medicine2026
Zebrafish tumor xenograft models for drug-screening: a systematic review of methods for treatment assessment.
Synthesis in Journal of translational medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Quantitative Preclinical Imaging as a Metrological Framework: Reproducibility, Validation, and Translational Maturity.Journal of imaging · 2026Review
- Zebrafish as a translational platform for investigating multi-organ pharmacological interactions of traditional Chinese medicine.Frontiers in pharmacology · 2026Review
- Self-Assembled Cationic Phthalocyanine Nanophotosensitizer Drives Hypoxia-Tolerant Photodynamic Immunotherapy for HCC.International journal of nanomedicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundZebrafish xenotransplantation models are increasingly employed as drug-screening platforms in precision oncology, offering the advantages of high replicate numbers and rapid data acquisition. Multiple strategies have been developed to evaluate anticancer therapies in zebrafish xenografts, varying in experimental design, methodology, and analytical approaches. However, a persistent limitation is the complexity of quantifying and automating drug-response measurements, which limits scalability and increases experimental workload. MATERIAL AND
methodsWe conducted a systematic review to summarize methodologies for evaluating drug efficacy in human cells xenografted into zebrafish larvae. A comprehensive search of PubMed, Scopus, and Web of Science yielded 113 eligible studies after a two-step screening process.
resultsThe review focused on two major aspects: xenotransplantation procedures and methods of drug-effect quantification. The analysis describes the injection of approximately 200 tumor cells into the embryos’ yolk sac, followed by a 72-hour treatment, representing the parameters most commonly employed. Drug efficacy was most frequently assessed by measuring tumor fluorescence intensity with a fluorescence stereomicroscope. Notably, 86.75% of studies tested five or fewer conditions per experiment.
conclusionIn conclusion, there is a clear need to develop standardized protocols that allow testing of a larger number of treatment conditions, thereby supporting the advancement of high-throughput drug screening platforms for personalized medicine.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.